POSELTINIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H26N6O3
Molecular Weight	470.523
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCN(CC1)C2=CC=C(NC3=NC4=C(OC=C4)C(OC5=CC(NC(=O)C=C)=CC=C5)=N3)C=C2

InChI

InChIKey=LZMJNVRJMFMYQS-UHFFFAOYSA-N

InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

HIDE SMILES / InChI

Molecular Formula	C26H26N6O3
Molecular Weight	470.523
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

C_max

Value	Dose	Analyte	Population
11.5 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
56.5 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
186 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
358 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
65.8 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
201 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33323529/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	POSELTINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
84.8 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
276 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1040 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2100 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
368 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03083561?tab=results	30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	POSELTINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1347 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33323529/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:	POSELTINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33323529/	30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered:		POSELTINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:09:21 GMT 2025` Edited by `admin` on `Mon Mar 31 23:09:21 GMT 2025`
Record UNII	D01E4B1U35
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

POSELTINIB

Official Name

English

poseltinib [INN]

Preferred Name

English

HM71224

Code

English

Poseltinib [WHO-DD]

Common Name

English

N-(3-((2-(4-(4-METHYLPIPERAZIN-1-YL)ANILINO)FURO(3,2-D)PYRIMIDIN-4-YL)OXY)PHENYL)PROP-2-ENAMIDE

Systematic Name

English

LY3337641

Code

English

2-PROPENAMIDE, N-(3-((2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)FURO(3,2-D)PYRIMIDIN-4-YL)OXY)PHENYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C124801